SRX Global Inc. Completes Private Placement Additional Closing

What Happened
SRX Global Inc. (f/k/a SRx Health Solutions) announced an additional closing under a Securities Purchase Agreement dated March 16, 2026. On July 27, 2026, the company issued and sold 4,340 shares of Series B convertible preferred stock and 284,156 warrants to purchase common stock for aggregate cash proceeds of approximately $3.472 million. This follows an initial closing on March 16, 2026 in which the company sold 5,660 shares of Series B preferred stock and 22,237,666 warrants for about $4.528 million.

Key Details

• Dates: Securities Purchase Agreement entered March 16, 2026; Additional Closing occurred July 27, 2026; 60-for-1 reverse stock split took effect July 2, 2026 (warrant count adjusted for split).
• Securities sold at Additional Closing: 4,340 Series B preferred shares and 284,156 warrants for ~ $3.472 million in cash.
• Aggregate under the agreement: initial and additional closings total 10,000 Series B preferred shares and aggregate proceeds of approximately $8.0 million.
• Registration/exemptions: Securities were sold in a private placement relying on Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D to accredited investors; securities are unregistered and subject to resale restrictions.

Why It Matters
This transaction completes the full $8.0 million placement contemplated by the March Securities Purchase Agreement, providing SRX Global with additional cash capital. Investors should note the company issued convertible preferred shares and a substantial number of warrants, which could lead to future dilution if converted or exercised. The securities are unregistered and were sold only to accredited investors, limiting immediate liquidity for those securities.